TrialsgrambetaRCTs are beautiful

RECOVERY (Dexamethasone)

2021

Dexamethasone in Hospitalised Patients with COVID-19

In 6,425 hospitalised patients with COVID-19, dexamethasone 6 mg/day × 10 d reduced 28-day mortality compared with usual care, in patients requiring oxygen or ventilation.

Result

Efficacy: 28-day all-cause mortalityRR 0.83 (95% CI 0.75-0.93)

Below 1 favours dexamethasone 6 mg/day × 10 d, above 1 favours usual care.

Event rates
Absolute difference
2.8 points
NNT
36

Absolute difference and NNT are derived from the event rates.

Also reported: Benefit only in patients on O₂ or mechanical ventilation.

Original publication
Subtopic
Corticosteroids
Design
Adaptive platform RCT, UK
Relevance
Practice-defining: a trial the field needs to know.
Source
RECOVERY Collaborative Group. N Engl J Med. 2021;384(8):693-704.doi 10.1056/NEJMoa2021436

Discussion & critique

The single largest treatment effect in the COVID-19 pandemic; transformed inpatient management.

Discussed in podcasts